# FDA 483 - Corixa Corporation - March 12, 2026

Source: https://www.keypedia.com/records/483/corixa-corporation/19a1395e-e985-4823-85ee-2f1a9c60144c

> FDA 483 for Corixa Corporation on March 12, 2026. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Corixa Corporation
- Inspection Date: 2026-03-12
- Product Type: drugs
- Office Name: FDA District Office — Philadelphia, Pennsylvania
- Summary: An FDA inspection of Corixa Corporation in Marietta, PA, a drug manufacturer, revealed a deficiency in the system for monitoring environmental conditions in aseptic processing areas. Specifically, the firm failed to properly qualify plates used for environmental monitoring samples at a required incubation temperature. This indicates a lapse in quality control for critical manufacturing processes.

## Related Officers

- [investigator](https://www.keypedia.com/people/priscilla-m-pastrana/170080d1-49da-42d7-8615-c774cac9f7ec)
- [Laurel A. Beer](https://www.keypedia.com/people/laurel-a-beer/0ac1e74f-0ff6-4db6-a0e8-0c3fb013720e)
- [Annette Melendez](https://www.keypedia.com/people/annette-melendez/bc1a065d-6408-4c4b-9dcf-c6884e8a75c4)

Company: https://www.keypedia.com/companies/corixa-corporation/540054c0-cf35-42d2-9056-a9ae897ff412

Office: https://www.keypedia.com/offices/fda-district-office-philadelphia-pennsylvania/e70a6e70-40b2-49e4-8360-c3db36c4d2a0